September 5, 2024, 5pm London time
Waste in cancer research has been disappointing to many whilst allowing significant capitalisation for pharmaceutical industry. Many improvements have been made and many more are yet to come. How should cancer research evolve? How can we decrease the waste and ensure better selection of pre-clinical models moving to clinic? Will we need phase 3 trials and what role RWE evidence will play? Will synthetic comparators give answers clinical practice needs? How can we overcome current incentives in the oncology market and stop over-production of expensive me-toos?
Speakers:
Chair: Dr. Leeza Osipenko
Dr. Marty Tenenbaum (Cancer Commons)
Dr. Julian Adams (Stand Up to Cancer)
Prof. Ian Tannock (University of Toronto)
Dr. Jonathan Kimmelman (McGill University)